Overview

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will determine the best doses of docetaxel and lonafarnib when the two anti-cancer agents are used in combination. Patients with tumors for which treatment with docetaxel would be appropriate are eligible. A second part of the study will further examine the effectiveness of the combination treatment in men with prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Docetaxel
Lonafarnib